Interested

• biochemistry molecular biology
• organic chemistry
• chemical physics
• general science technology
• biotechnology
• nanoscience nanotechnology
• medicinal biomolecular chemistry
• polymers
• immunology
• pharmacology pharmacy

Scientific discipline

• medical sciences
• biomedical engineering

Latest publications

• Multivalent protein-drug conjugates – an emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells
• FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent manner.
• Fibroblast growth factor 2 conjugated with monomethyl auristatin E inhibits tumor growth in a mouse model.
• Intracellular FGF1 protects cells from apoptosis through direct interaction with p53
• Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.
• Nuclear localization sequence of FGF1 is not required for its intracellular anti-apoptotic activity in differentiated cells.
• Cross-talk between fibroblast growth factor receptors and other cell surface proteins.
• Site-specific, stoichiometric-controlled, PEGylated conjugates of fibroblast growth factor 2 (FGF2) with hydrophilic auristatin Y for highly selective killing of cancer cells overproducing fibroblast growth factor receptor 1 (FGFR1).
• Stable fibroblast growth factor 2 dimers with high pro-survival and mitogenic potential.
• Intrinsically fluorescent oligomeric cytotoxic conjugates toxic for FGFR1-overproducing cancers.
• Drug conjugation via maleimide–thiol chemistry does not affect targeting properties of cysteine-containing anti-FGFR1 peptibodies.
• Dual-warhead conjugate based on fibroblast growth factor 2 dimer loaded with α-amanitin and monomethyl auristatin E exhibits superior cytotoxicity towards cancer cells overproducing fibroblast growth factor receptor 1
• Low stability of integrin-binding deficient mutant of FGF1 restricts its biological activity.
• Crosstalk between p38 and Erk 1/2 in downregulation of FGF1-induced signaling.
• FGF2-derived peptibodyF2-MMAE conjugate for targeted delivery of cytotoxic drugs into cancer cells overexpressing FGFR1.
• FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance.
• Novel method for preparation of site-specific, stoichiometric-controlled dual warhead conjugate of FGF2 via dimerization employing sortase a-mediated ligation.
• Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions.
• FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization.
• Targeting cellular trafficking of fibroblast growth factor receptors as a strategy for selective cancer treatment.